Outrage against PBMs was on full display when 400 pharmacy professionals in Kansas shuttered their businesses and petitioned ...

Healthcare startup Capital Rx seeing revenue surge as Congress seeks to regulate the PBM giants that profit from high drug ...

In 2021, operating income from these PBMs' affiliated pharmacies from specialty generics totaled 12% of all operating income for the parent corporations' business segments. The Big 3 PBMs are ...

When it comes to high drug costs for consumers, pharmacy benefit managers are not the villains, the new CVS chief executive said Wednesday.

The agency’s report found that the “Big 3 PBMs” – CVS Health’s (CVS) Caremark Rx, UnitedHealth’s (UNH) OptumRx, and Cigna’s (CI) Express Scripts – marked up “numerous specialty ...

Discover how the three largest pharmacy benefit managers are rejecting biosimilars from their formularies, except for their own private-label drugs.

We spoke recently with Craig Burton, MBA, executive director of the Biosimilars Council, a trade and lobbying group for the ...

The "Big 3" PBMs also separately generated an estimated $1.4 billion of income from spread pricing, FTC finds. Jeff Lagasse, Editor Healthcare lease accounting insights: How two organizations got ...

The report found that these “Big 3” pharmacy benefit managers (PBMs) in the U.S. pocketed about $7.3 billion in excess revenue between 2017 and 2022 by marking up certain medicines by ...

Staff’s latest report found that the ‘Big 3 PBMs’—Caremark Rx, LLC (CVS), Express Scripts, Inc. (ESI), and OptumRx, Inc. (OptumRx)—marked up numerous specialty generic drugs dispensed at ...

A new FTC report found that pharmacy benefit managers have inflated the price of life-saving generic prescription drugs, ...

The investigation revealed the three biggest PBMs undertook a variety of actions that boosted their earnings but increased costs for plan sponsors, taxpayers and patients, according to the FTC.